Nursing Elites

1. A client has a new prescription for Enoxaparin. Which of the following instructions should the nurse include?

• A. Massage the injection site after administration.
• B. Aspirate before injecting the medication.
• C. Administer the medication into the abdomen.
• D. Administer the medication via intramuscular injection.

Correct answer: C

Rationale: The correct answer is to administer the medication into the abdomen. Enoxaparin is a medication that is administered subcutaneously, typically in the abdomen to ensure proper absorption. Massaging the injection site should be avoided as it can lead to bruising or bleeding under the skin. Aspirating before injecting the medication is not necessary for subcutaneous injections like Enoxaparin. Administering the medication via intramuscular injection is incorrect as Enoxaparin should be given subcutaneously.

2. A client is receiving treatment with irinotecan. Which of the following findings should the nurse monitor?

• A. Diarrhea
• B. Hypertension
• C. Ototoxicity
• D. Neutropenia

Correct answer: A

Rationale: Corrected Rationale: Irinotecan is known to commonly cause diarrhea as an adverse effect due to its impact on the gastrointestinal tract. Therefore, the nurse should closely monitor the client for signs of diarrhea while receiving this treatment. Choices B, C, and D are incorrect because irinotecan is not typically associated with hypertension, ototoxicity, or neutropenia as primary adverse effects. While these side effects can occur with other medications, they are not the main concerns when monitoring a client receiving irinotecan.

3. A client is to receive Pamidronate for bone pain related to cancer. What precaution should the nurse take during the administration of Pamidronate?

• A. Inspect the skin for redness and irritation around the injection site.
• B. Assess the IV site for thrombophlebitis frequently during administration.
• C. Instruct the client to lie down for 30 minutes after oral administration.
• D. Monitor for signs of anaphylaxis for 20 minutes after intramuscular injection.

Correct answer: B

Rationale: Pamidronate is typically administered through IV infusion, which can cause irritation to veins. The nurse should frequently assess the IV site for thrombophlebitis during the administration to promptly detect any potential complications related to the infusion. Inspecting the skin for redness and irritation around the injection site (Choice A) is not directly related to IV infusion. Instructing the client to lie down after oral administration (Choice C) is not necessary for IV administration. Monitoring for signs of anaphylaxis after an intramuscular injection (Choice D) is not relevant for an IV infusion of Pamidronate.

4. A client with renal failure and an elevated phosphorus level is prescribed aluminum hydroxide 300 mg PO three times daily. For which of the following adverse effects should the nurse inform the client?

• A. Constipation
• B. Metallic taste
• C. Headache
• D. Muscle spasms

Correct answer: A

Rationale: Correct. Aluminum hydroxide is known to cause constipation as a common side effect. Instructing the client about this potential adverse effect is important for their awareness and management. The other options, metallic taste, headache, and muscle spasms, are not typically associated with aluminum hydroxide use. Therefore, the nurse should focus on educating the client about the increased risk of constipation and provide guidance on managing this side effect to improve the client's comfort and treatment adherence.

5. What should you monitor when administering Clopidogrel to a patient?

• A. Signs of thrombotic thrombocytopenic purpura
• B. Bleeding during therapy
• C. CBC with differential and platelet count
• D. All of the above

Correct answer: D

Rationale: When administering Clopidogrel, it is crucial to monitor for signs of thrombotic thrombocytopenic purpura, bleeding during therapy, and changes in CBC with differential and platelet count. Thrombotic thrombocytopenic purpura is a rare but serious condition associated with Clopidogrel use, characterized by microangiopathic hemolytic anemia, thrombocytopenia, neurological symptoms, fever, and renal dysfunction. Monitoring for signs of thrombotic thrombocytopenic purpura is essential to detect this potentially life-threatening condition early. Monitoring for bleeding helps to assess the risk of hemorrhagic events, a known side effect of Clopidogrel. Additionally, regular monitoring of CBC with differential and platelet count is necessary to evaluate the drug's impact on blood cell counts and detect any abnormalities that may require intervention. Therefore, monitoring all these parameters is vital to ensure patient safety and appropriate management during Clopidogrel therapy.

Similar Questions